SART.F Stock Overview
Provides bioprocess solutions and lab products and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €195.24 |
| 52 Week High | €313.00 |
| 52 Week Low | €175.93 |
| Beta | 0.93 |
| 11 Month Change | -1.01% |
| 3 Month Change | -3.78% |
| 1 Year Change | -18.99% |
| 33 Year Change | -66.63% |
| 5 Year Change | n/a |
| Change since IPO | 813.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| SART.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.6% | -9.0% | -2.1% |
| 1Y | -19.0% | 2.9% | 29.7% |
Return vs Industry: SART.F underperformed the US Life Sciences industry which returned 4.9% over the past year.
Return vs Market: SART.F underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| SART.F volatility | |
|---|---|
| SART.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SART.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SART.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 13,762 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products.
Sartorius Aktiengesellschaft Fundamentals Summary
| SART.F fundamental statistics | |
|---|---|
| Market cap | US$14.14b |
| Earnings (TTM) | US$81.27m |
| Revenue (TTM) | US$3.50b |
191.9x
P/E Ratio4.5x
P/S RatioIs SART.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SART.F income statement (TTM) | |
|---|---|
| Revenue | €3.32b |
| Cost of Revenue | €1.82b |
| Gross Profit | €1.50b |
| Other Expenses | €1.43b |
| Earnings | €77.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 45.22% |
| Net Profit Margin | 2.32% |
| Debt/Equity Ratio | 115.4% |
How did SART.F perform over the long term?
See historical performance and comparison